索引超出了数组界限。 文章摘要
|本期目录/Table of Contents|

[1]金慧 张振刚 袁晓晨.非瓣膜性心房颤动卒中风险评估研究进展[J].国际心血管病杂志,2019,06:324-327.
点击复制

非瓣膜性心房颤动卒中风险评估研究进展(PDF)

《国际心血管病杂志》[ISSN:1006-6977/CN:61-1281/TN]

期数:
2019年06期
页码:
324-327
栏目:
综述
出版日期:
2019-12-31

文章信息/Info

Title:
-
作者:
金慧 张振刚 袁晓晨
225000 扬州大学附属医院心血管内科
Author(s):
-
关键词:
心房颤动;  卒中危险分层;  左心房;  生物标志物;  基因多态性
Keywords:
-
分类号:
-
DOI:
10.3969/j.issn.1673-6583.2019.06.002
文献标识码:
-
摘要:
心房颤动(AF)患者发生卒中的风险较高。CHA2DS2-VASc评分、ATRIA评分和ABC评分是临床常用的房颤卒中风险评估。研究显示,衡量左房大小的超声指标及其相关衍生数据模型、生物标志物、基因多态性等也可以对房颤卒中风险进行评估。该文介绍非瓣膜性心房颤动卒中风险评估的研究进展。
Abstract:
-

参考文献/References

[ 1 ] Glotzer TV, Ziegler PD. Cryptogenic stroke: is silent atrial fibrillation the culprit?[J]. Heart Rhythm, 2015, 12(1):234-241.
[ 2 ] January CT, Wann LS, Alpert JS, et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the heart rhythm society[J]. Circulation, 2014, 130(23):2071-2104.
[ 3 ] Hijazi Z, Lindback J, Alexander JH, et al. The ABC(age, biomarkers, clinical history)stroke risk score: a biomarker-based risk score for predicting stroke in atrial fibrillation[J]. Eur Heart J, 2016, 37(20):1582-1590.
[ 4 ] Giralt-Steinhauer E, Cuadrado-Godia E, Ois A, et al. Comparison between CHADS2 and CHA2DS2-VASc score in a stroke cohort with atrial fibrillation[J]. Eur J Neurol, 2013, 20(4):623-628.
[ 5 ] Kirchhof P, Benussi S, Kotecha D, et al. 2016 ESC guidelines for the management of atrial fibrillation developed in collaboration with EACTS[J].Rev Esp Cardiol(Engl Ed), 2017, 70(1):50.
[ 6 ] Aspberg S, Chang Y, Atterman A, et al. Comparison of the ATRIA, CHADS2, and CHA2DS2-VASc stroke risk scores in predicting ischaemic stroke in a large Swedish cohort of patients with atrial fibrillation[J]. Eur Heart J, 2016, 37(42):3203-3210.
[ 7 ] Zabalgoitia M, Halperin JL, Pearce LA, et al. Transesophageal echocardiographic correlates of clinical risk of thromboembolism in nonvalvular atrial fibrillation. Stroke prevention in atrial fibrillation Ⅲ investigators[J]. J Am Coll Cardiol, 1998, 31(7):1622-1626.
[ 8 ] Lee JM, Shim J, Uhm JS, et al. Impact of increased orifice size and decreased flow velocity of left atrial appendage on stroke in nonvalvular atrial fibrillation[J]. Am J Cardiol, 2014, 113(6):963-969.
[ 9 ] Black IW. Spontaneous echo contrast: where there's smoke there's fire[J]. Echocardiography, 2000, 17(4):373-382.
[10] Markl M, Lee DC, Ng J, et al. Left atrial 4-dimensional flow magnetic resonance imaging stasis and velocity mapping in patients with atrial fibrillation[J]. Invest Radiol, 2016, 51(3):147-154.
[11] Masci A, Barone L, Dedè L, et al. The impact of left atrium appendage morphology on stroke risk assessment in atrial fibrillation: a computational fluid dynamics study[J]. Front Physiol, 2019, 9:1938.
[12] Jankajova M, Kubikova L, Valocik G, et al. Left atrial appendage strain rate is associated with documented thromboembolism in nonvalvular atrial fibrillation[J]. Wien Klin Wochenschr, 2019, 131(7/8):156-164.
[13] Szegedi I, Szapary L, Csecsei P, et al. Potential biological markers of atrial fibrillation: a chance to prevent cryptogenic stroke[J]. Biomed Res Int, 2017, 2017:8153024.
[14] Chang SN, Lai LP, Chiang FT, et al. C-reactive protein gene polymorphism predicts the risk of thromboembolic stroke in patients with atrial fibrillation: a more than 10-year prospective follow-up study[J]. J Thromb Haemost, 2017, 15(8):1541-1546.
[15] Li M, Yang G, Xie B, et al. Changes in matrix metalloproteinase-9 levels during progression of atrial fibrillation[J]. J Int Med Res, 2014, 42(1):224-230.
[16] Hijazi Z, Verdecchia P, Oldgren J. Cardiac biomarkers and left ventricular hypertrophy in relation to outcomes in patients with atrial fibrillation:experiences from the RE-LY trial[J]. J Am Heart Assoc, 2019, 8(2):e010107.
[17] Watson T, Shantsila R, Gyh L. Mechanisms of thrombogenesis in atrial fibrillation:vircow's triad revisited[J]. Lancet, 2009, 373(9668):155-166.
[18] Silvet H, Young-Xu Y, Walleigh D, et al. Brain natriuretic peptide is elevated in outpatients with atrial fibrillation[J]. Am J Cardiol, 2003, 92(9):1124-1127.
[19] Neeland IJ, Drazner MH, Berry JD, et al. Biomarkers of chronic cardiac injury and hemodynamic stress identify a malignant phenotype of left ventricular hypertrophy in the general population[J]. J Am Coll Cardiol, 2013, 61(2):187-195.
[20] Suissa L, Bresch S, Lachaud S, et al. Brain natriuretic peptide:a relevant marker to rule out delayed atrial fibrillation in stroke patient[J].J Stroke Cerebrovasc Dis, 2013, 22(7):e103-e110.
[21] Saliba W, Barnett-Griness O, Elias M, et al. Neutrophil to lymphocyte ratio(NLR)and risk of first episode stroke in patients with atrial fibrillation: a cohort study[J]. J Thromb Haemost, 2015, 13(11):1971-1979.
[22] Kocyigit D, Gurses KM, Yalcin MU, et al. Serum galectin-3 level as a marker of thrombogenicity in atrial fibrillation[J]. J Clin Lab Anal, 2017, 31(6):e22120.
[23] Ellinor PT, Lunetta KL, Albert CM, et al. Meta-analysis identifies six new susceptibility loci for atrial fibrillation[J]. Nat Genet, 2012, 44(6):670-675.
[24] Sinner MF, Tucker NR, Lunetta KL, et al. Integrating genetic, transcriptional, and functional analyses to identify 5 novel genes for atrial fibrillation[J]. Circulation, 2014, 130(15):1225-1235.
[25] Tada H, Shiffman D, Smith JG, et al. Twelve-single nucleotide polymorphism genetic risk score identifies individuals at increased risk for future atrial fibrillation and stroke[J]. Stroke, 2014, 45(10):2856-2862.
[26] Lubitz SA, Parsons OE, Anderson CD, et al. Atrial fibrillation genetic risk and ischemic stroke mechanisms[J]. Stroke, 2017, 48(6):1451-1456.
[27] Glotzer TV, Daoud EG, Wyse DG, et al. The relationship between daily atrial tachyarrhythmia burden from implantable device diagnostics and stroke risk the TRENDS study[J]. Circ Arrhythm Electrophysiol, 2009, 2(5):474-480.

备注/Memo

备注/Memo:
作者单位:225000 扬州大学附属医院心血管内科
通信作者:袁晓晨,Email:13665288033@163.com
更新日期/Last Update: 2019-12-27